pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Wegovy · news · pharmadog
← back to Wegovy
News mentioning Wegovy
87
stories
May 28, 26
CVS obesity drug deal puts Lilly on equal footing with Novo
biopharma dive
May 13, 26
Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss
biopharma dive
May 13, 26
STAT+: Pharmalittle: We’re reading about FDA’s Makary resigning, a Lilly weight loss drug trial, and more
stat
May 12, 26
STAT+: Pharmalittle: We’re reading about pharma lobbying, Bristol’s deal with a Chinese partner, and more
stat
May 11, 26
Rezdiffra is exceeding Wall Street's expectations as the MASH market takes shape
endpoints
May 7, 26
Amazon adds Ozempic pill to same-day prescription drug kiosks
endpoints
May 7, 26
Entrada stock falls on Duchenne data; Wegovy expands access
endpoints
May 7, 26
STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
stat
May 7, 26
STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
stat
May 7, 26
STAT+: Next-gen Duchenne drug from Entrada disappoints
stat
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 6, 26
STAT+: Oregon hospitals won’t outsource to national physician chain after all
stat
May 6, 26
STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’
stat
May 6, 26
Novo hikes guidance on Wegovy pill’s fast sales start
biopharma dive
May 6, 26
STAT+: How a global effort to explore the ‘dark proteome’ is upending our understanding of human disease
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 6, 26
Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressure
endpoints
May 5, 26
Second life for gene therapy; Takeda Phase 2/3 win; UK cancer biotech's $83M
endpoints
May 4, 26
STAT+: French regulator fines Novo and Lilly over weight loss ad campaigns
stat
May 1, 26
STAT+: Pharmalittle: We’re reading about obesity drugs and a compounding list, an AstraZeneca setback, and more
stat
Apr 30, 26
STAT+: FDA wants to exclude weight loss drugs from a compounding list
stat
Apr 30, 26
Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch
biopharma dive
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.
biopharma dive
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
Apr 25, 26
Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
stat
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
← prev
page 3 of 3
next →
